F.G.J. (Friso) Calkoen

Knowledge & experience

Specialism / subspecialism:

Experience

• 2002-2009    Medical school LUMC
• 2009-2013    Phd program Willem Alexander Kinderziekenhuis, Leiden: Mesenchymal stromal cells in pediatric disease
• 2014-2018    Resident in pediatrics LUMC/JKZ
• 2018-2020    Fellow pediatric oncology Princess Máxima Center
• 2021-             Pediatric oncologist

Key publications

• Zwaan CM, Calkoen FGJ. Immunotherapy: genetically agnostic in BCP-ALL? Blood. 2022 Apr 7;139(14):2093-2094
  
• Rozowsky JS, Meesters-Ensing JI, Lammers JAS, Belle ML, Nierkens S, Kranendonk MEG, Kester LA, Calkoen FG, van der Lugt J. A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies. Front Immunol 2022 Apr 7;13:864423
• Dekker L*, Calkoen FGJ* , Jiang Y, Blok H, Veldkamp SR, De Koning C, Spoon M, Admiraal R, Hoogerbrugge P, Vormoor B, Vormoor HJ, Visscher H, Bierings M, Van Der Vlugt M, Van Tinteren H, Nijstad AL, Huitema ADR, Van Der Elst KCM, Pieters R, Lindemans CA, Nierkens S. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022 Apr 12;6(7): 1969-1976
•  Buechner J, Caruana I, Künkele, Rives S, Vettenranta K, Bader P, Peters C, Baruchel A, Calkoen FGJ. Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant? Frontiers in pediatrics. 2022 Jan 25;9:784024
• Calkoen FGJ, Vervat C, Eising E, Vijfhuizen LS, ‘t Hoen PB, van den Heuvel-Eibrink MM, Egeler RM, van Tol MJ, Ball LM. Gene-expression and in vitro function of mesenchymal stromal cells are affected in juvenile myelomonocytic leukemia. Haematologica. 2015; 100(11):1434-41.

Contact details